Leukocyte Telomere Length and Risk of Secondary Primary Tumors in Long-Term Breast Cancer Survivors

Maria Alma Rodriguez,Beatriz Sanchez-Espiridion,Jian Gu,Xifeng Wu,Frances Ann Zandstra,Guadalupe R. Palos
DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.9599
IF: 45.3
2014-01-01
Journal of Clinical Oncology
Abstract:9599 Background: Leukocytetelomere length (LTL) has been associated with cancer risk including breast cancer. Telomere shortening is observed in response to chemotherapy and/or ionizing radiation exposure. More recently, a report has shown a significant association between short LTL and increased risk of treatment-related thyroid cancer, whereas a suggestive, non-significant association was found between LTL and treatment-related breast cancer (Gramatges MA, et al. Clin Cancer Res, Nov. 2013). We hypothesize that LTL at diagnosis may be associated with breast cancer survival and risk of developing secondary primary tumors (SPT) in long-term breast cancer survivors. We used a case-control study to test this hypothesis. Methods: We used a quantitative real-time PCR method to measure LTL in 168 long term breast cancer survivors (including 68 with SPT, and 100 without SPT), 96 newly diagnosed breast cancer cases, and 97 controls. Cases and controls were matched by years since diagnosis, age at time of sample collection and race. Wilcoxon-rank sum test was used to compare LTL among these three groups and between those long-term survivors with and without SPT. Results: We found that LTL was significantly longer in long-term breast cancer survivors than newly-diagnosed breast cancer patients (Mean (SD), 1.31 ±0.26 vs 1.22 ±0.31; p=0.005), and healthy controls (1.31±0.26 vs 1.10±0.30, p<0.001). Overall, there were no significant differences in LTL between long term survivors with SPT and without SPT. However, in stratified analyses, we observed that breast cancer survivors with SPT had significantly or borderline significantly shorter LTL than those without SPT in individuals with low BMI (<=25) (1.23±0.19 vs 1.44±0.25; p<0.006) and in ever smokers (1.21±0.31 vs 1.36 ±0.32, p =0.071). Conclusions: Longer telomeres were observed in long term breast cancer survivors when compared to new diagnosed cases and healthy controls. A relation between short LTL and increased risk of SPT in long term breast cancer survivors was observed in individuals with low BMI and ever smokers. These results suggest a role of telomere dysfunction in long term breast cancer survivorship.
What problem does this paper attempt to address?